# Round 1 Product Brief — WS01 WSTERA Supply Management

Repo: `D:\AI-Workspace\projects\saas-product-hub\products\WSM`
Output: `round1-product-reviews/WS01-WSM.md`

## Objective
Determine whether WSM's locked supply-operations model should become a commercial SaaS, a narrower operational tool, or another destination before any Phase 1 implementation begins.

## Mandatory sources
Verify Git state first, then inspect at minimum:
- `docs/00_PRODUCT_VISION.md`
- `docs/01_PRD.md`
- `docs/02_SYSTEM_ARCHITECTURE.md`
- `docs/03_DATA_SECURITY_TENANCY.md`
- `docs/04_PRICING_ENTITLEMENTS.md`
- `docs/05_SUPPLY_DOMAIN_RULES.md`
- `docs/06_UX_USER_FLOWS.md`
- `docs/08_EXTERNAL_DEPENDENCIES.md`
- `docs/10_DEVELOPMENT_ROADMAP.md`
- `docs/PRODUCT_DECISIONS.md`
- `docs/CURRENT_STATUS.md`
- authoritative Phase 1 schema/domain contracts and independent Documentation Lock review

## Questions specific to WS01
- Who exactly is the buyer: importer, distributor, purchasing team, factory coordinator, or another evidenced role?
- What recurring operational pain makes WSM worth paying for versus spreadsheet/LINE workflows?
- What is the smallest end-to-end supply loop that proves value?
- Which locked Phase 1 invariants are product-defining and which are implementation detail?
- Is multi-tenant SaaS justified by the buyer/problem, or is another delivery model stronger?
## Module scan focus
Evaluate auth/tenant, audit, import-export, notification, job/retry, scheduler, payment/subscription and config/runtime only against the chosen destination. Identify capabilities that should remain product-native versus copied shared infrastructure.

## Required output
Produce the standard destination card plus: buyer definition, spreadsheet/LINE replacement argument, thin sellable loop, runtime/commercial unknowns, and whether the Phase 1 build brief should remain authorized after Council.

## Boundary
No Phase 1 build brief, migration, scaffold, schema implementation or production-placement decision may be created by this review. Documentation Lock is evidence, not implementation authorization.